Navigation Links
AssureRx Adds VP of Sales and Marketing
Date:4/28/2008

Personalized medicine company prepares for commercial launch of first

product

CINCINNATI, April 28 /PRNewswire/ -- AssureRx, a personalized medicine company, announced that Al Lucas has joined the Company as vice president of sales and marketing. He will be responsible for developing the marketing plan and initial launch strategy, building the sales force, and leading the commercial introduction of the Company's first product. Lucas is an experienced pharmaceutical sales and marketing leader with more than 20 years of experience at companies such as Novartis, Pharmacia, and The Upjohn Company. In his various roles with those companies, he has participated in more than 15 successful product launches, including the highly successful Zyvox (linezolid). Additionally, he played roles in the planning, hiring and training of multiple sales forces.

"I was very excited about the opportunity to join AssureRx in this early stage," said Lucas. "The personalized medicine movement will change the way medicine is practiced, and AssureRx has positioned itself to become the market leader within the largest potential segment, the neuropsychiatric field. The Company has solid relationships with the thought leaders in psychopharmacogenetic research, which supports the development of our products. We will leverage this cutting-edge technology to bring tools to the marketplace which will help physicians provide individualized and highly-specific care to each patient," Lucas continued. "These are the hallmarks of personalized medicine."

Mark Byrne, AssureRx CEO added, "We are extremely pleased that Al has joined AssureRx. He brings a demonstrated track record of successful new product introductions and is experienced in the neuro-pscyh market segment. The addition of Al will accelerate our commercial introduction."

About AssureRx

AssureRx, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize the industry-leading personalized medicine technology of Cincinnati Children's Hospital and the Mayo Clinic. The proprietary technology is based on pharmacogenetics -- the study of the genetic factors that influence an individual's response to drug treatments -- as well as evidence-based medicine and clinical pharmacology. The result is a trusted guide that helps doctors select the right drug at the right dose right now.


'/>"/>
SOURCE AssureRx, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
2. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
6. Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business
7. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
8. Dilon Technologies Closes First Quarter With Record Sales
9. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... ... compliance training, today announced an interactive FDA compliance training course, ... (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available on ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... takes place February 5-6 at the University’s student center, Kehr Union, located ... as workshops and competitions for ample networking, learning and collaborating opportunities. , ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
Breaking Biology Technology:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):